FibroGen grapples with PhIII setback in Duchenne muscular dystrophy
FibroGen’s top antibody candidate has failed a Phase III study in Duchenne muscular dystrophy, marking a disappointing start to a string …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.